Among New Drug Launches, Oncology Scores Big While CV Lags
Bristol’s Opdivo and Pfizer’s Ibrance are standouts among recent drug launches, well on their way to becoming commercial blockbusters, while new cardiovascular drugs like Repatha, Praluent and Entresto, forecast to become blockbusters in their own right, have been slow at launch, restrained by market access.
You may also be interested in...
Pfizer's first-in-class breast cancer drug Ibrance is set to debut in South Korea following a regulatory approval and will offer a new option for the growing number of patients in the country.
With the launch of Ibrance and a burgeoning immuno-oncology program, Pfizer’s oncology business is on track to generate substantial revenue and investors are starting to take note. Oncology President Liz Barrett and Chief Medical Officer Mace Rothenberg discuss Pfizer’s initiative to become a leader in the field.
The company reported positive data from two Phase IIIb trials testing RelabotulinumtoxinA and said it hopes to refile a BLA for the aesthetic dermatology product soon.